Kissei Pharmaceutical Co., Ltd.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1946-08-09
- Employees
- 1.7K
- Market Cap
- -
- Website
- http://www.kissei.co.jp
An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Phase 3
Completed
- Conditions
- Spinocerebellar Degeneration
- Interventions
- Drug: KPS-0373, High doseDrug: KPS-0373, Low dose
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2016-04-18
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Registration Number
- NCT01970111
A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Phase 3
Completed
- Conditions
- Spinocerebellar Degeneration
- Interventions
- Drug: KPS-0373, High doseDrug: KPS-0373, Low dose
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2016-04-18
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Registration Number
- NCT01970137
A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Phase 3
Completed
- Conditions
- Spinocerebellar Degeneration
- Interventions
- Drug: KPS-0373, High doseDrug: PlaceboDrug: KPS-0373, Low dose
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 374
- Registration Number
- NCT01970098
A Single-blind, Dose-titration Study of KWA-0711 in Patients With Chronic Constipation
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Registration Number
- NCT01938196
A Single-blind, Dose-tapering Study of KWA-0711 in Patients With Chronic Constipation
- First Posted Date
- 2013-09-09
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Registration Number
- NCT01937663
A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes
Phase 2
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- Drug: KCT-0809 ophthalmic solutionDrug: Placebo
- First Posted Date
- 2013-07-02
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Registration Number
- NCT01890941
A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia
- First Posted Date
- 2013-05-14
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Registration Number
- NCT01852682
A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia
- First Posted Date
- 2013-05-09
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT01850641
A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Phase 3
Completed
- Conditions
- HyperphosphatemiaHemodialysis
- Interventions
- First Posted Date
- 2013-05-09
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 213
- Registration Number
- NCT01850602
A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 161
- Registration Number
- NCT01833494
- Locations
- 🇯🇵
JAPAN, Multiple Locations, Japan
© Copyright 2025. All Rights Reserved by MedPath